Insulet Shares Slump on Concerns of New Diabetes Drugs Sales

Insulet Corp's shares hit an over 3-year low on Thursday on concerns that strong demand for a new class of diabetes drugs that also aid in weight loss could hit sales of its insulin pumps.

Related Keywords

Bengaluru ,Karnataka ,India ,Shinjini Ganguli ,James Hollingshead ,Bhanvi Satija ,Novo Nordisk ,Reuters ,Insulet Corp ,Wells Fargo Healthcare Conference ,New England Journal ,Massachusetts Based Insulet ,Anild Silva ,Weight Management ,Diabetes Mellitus Type 1 ,Iabetes Mellitus Type I ,Type 1 Diabetes ,Glp 1 Receptor Agonists ,Glucagon Like Peptide 1 Receptor Agonists ,Incretin Hormones ,Incretins ,Weight Loss ,Obesity ,Bese ,Insulin Pump ,Continuous Subcutaneous Insulin Infusion ,Insulin Therapy ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,